Parathyroid carcinoma

Clinical Oncology

Volumn 22, Issue 6, 2010, Pages 498-507

  Givi, B ^a   Shah, J P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Parathyroid carcinoma; Surgical management

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITONIN; CALCIUM; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBIN; FLUOROURACIL; MITHRAMYCIN; PARATHYROID HORMONE; UNCLASSIFIED DRUG; VINCRISTINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;

ARTICLE; CALCIUM BLOOD LEVEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SUSCEPTIBILITY; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; HUMAN; HYPERCALCEMIA; MOLECULAR BIOLOGY; PARATHYROID CARCINOMA; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COMPLICATION; FEMALE; GENETICS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARATHYROID NEOPLASMS;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERCALCEMIA; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PARATHYROID NEOPLASMS; PROGNOSIS;

EID: 77954762333     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.04.007     Document Type: Article

References (123)

1. Beus K.S., Stack B.C. Parathyroid carcinoma. Otolaryngol Clin N Am 2004, 37:845-854. x.
2. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1999, 86:538-544.
3. Koea J.B., Shaw J.H. Parathyroid cancer: biology and management. Surg Oncol 1999, 8:155-165.
4. Rao S.R., Shaha A.R., Singh B., Rinaldo A., Ferlito A. Management of cancer of the parathyroid. Acta Otolaryngol 2002, 122:448-452.
5. Rawat N., Khetan N., Williams D.W., Baxter J.N. Parathyroid carcinoma. Br J Surg 2005, 92:1345-1353.
6. De Quervain F. Parastruma maligna aberrata. Deutsche Zeitschr Chir 1904, 100:334-352.
7. Marcocci C., Cetani F., Rubin M.R., Silverberg S.J., Pinchera A., Bilezikian J.P. Parathyroid carcinoma. J Bone Miner Res 2008, 23:1869-1880.
8. Cohn K., Silverman M., Corrado J., Sedgewick C. Parathyroid carcinoma: the Lahey Clinic experience. Surgery 1985, 98:1095-1100.
9. Hakaim A.G., Esselstyn C.B. Parathyroid carcinoma: 50-year experience at the Cleveland Clinic Foundation. Cleve Clin J Med 1993, 60:331-335.
10. Wang C.A., Gaz R.D. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg 1985, 149:522-527.
11. Shane E., Bilezikian J.P. Parathyroid carcinoma: a review of 62 patients. Endocr Rev 1982, 3:218-226.
12. Sandelin K., Auer G., Bondeson L., Grimelius L., Farnebo L.O. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg 1992, 16:724-731.
13. Kodama T., Ito Y., Obara T., et al. Nippon Geka Gakkai Zasshi 1988, 89:398-407.
14. Obara T., Okamoto T., Kanbe M., Iihara M. Functioning parathyroid carcinoma: clinicopathologic features and rational treatment. Semin Surg Oncol 1997, 13:134-141.
15. Hamill J., Maoate K., Beasley S.W., Corbett R., Evans J. Familial parathyroid carcinoma in a child. J Paediatr Child Health 2002, 38:314-317.
16. Ireland J.P., Fleming S.J., Levison D.A., Cattell W.R., Baker L.R. Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck. J Clin Pathol 1985, 38:1114-1118.
17. Christmas T.J., Chapple C.R., Noble J.G., Milroy E.J., Cowie A.G. Hyperparathyroidism after neck irradiation. Br J Surg 1988, 75:873-874.
18. Cohen J., Gierlowski T.C., Schneider A.B. A prospective study of hyperparathyroidism in individuals exposed to radiation in childhood. J Am Med Assoc 1990, 264:581-584.
19. Rasmuson T., Damber L., Johansson L., Johansson R., Larsson L.G. Increased incidence of parathyroid adenomas following X-ray treatment of benign diseases in the cervical spine in adult patients. Clin Endocrinol (Oxf) 2002, 57:731-734.
20. Dionisi S., Minisola S., Pepe J., et al. Concurrent parathyroid adenomas and carcinoma in the setting of multiple endocrine neoplasia type 1: presentation as hypercalcemic crisis. Mayo Clin Proc 2002, 77:866-869.
21. Agha A., Carpenter R., Bhattacharya S., Edmonson S.J., Carlsen E., Monson J.P. Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest 2007, 30:145-149.
22. Haven C.J., van Puijenbroek M., Tan M.H., et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf) 2007, 67:370-376.
23. Jenkins P.J., Satta M.A., Simmgen M., et al. Metastatic parathyroid carcinoma in the MEN2A syndrome. Clin Endocrinol (Oxf) 1997, 47:747-751.
24. Dinnen J.S., Greenwoood R.H., Jones J.H., Walker D.A., Williams E.D. Parathyroid carcinoma in familial hyperparathyroidism. J Clin Pathol 1977, 30:966-975.
25. Wynne A.G., van Heerden J., Carney J.A., Fitzpatrick L.A. Parathyroid carcinoma: clinical and pathologic features in 43 patients. Medicine (Baltimore) 1992, 71:197-205.
26. Wassif W.S., Moniz C.F., Friedman E., et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab 1993, 77:1485-1489.
27. Simonds W.F., James-Newton L.A., Agarwal S.K., et al. Familial isolated hyperparathyroidism: clinical and genetic characteristics of 36 kindreds. Medicine (Baltimore) 2002, 81:1-26.
28. Kytola S., Farnebo F., Obara T., et al. Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 2000, 157:579-586.
29. Cryns V.L., Thor A., Xu H.J., et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med 1994, 330:757-761.
30. Cetani F., Pardi E., Viacava P., et al. A reappraisal of the Rb1 gene abnormalities in the diagnosis of parathyroid cancer. Clin Endocrinol (Oxf) 2004, 60:99-106.
31. Cryns V.L., Rubio M.P., Thor A.D., Louis D.N., Arnold A. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab 1994, 78:1320-1324.
32. Pearce S.H., Trump D., Wooding C., Sheppard M.N., Clayton R.N., Thakker R.V. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptibility (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol (Oxf) 1996, 45:195-200.
33. Shattuck T.M., Kim T.S., Costa J., et al. Mutational analyses of RB and BRCA2 as candidate tumour suppressor genes in parathyroid carcinoma. Clin Endocrinol (Oxf) 2003, 59:180-189.
34. Arnold A., Shattuck T.M., Mallya S.M., et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res 2002, 17(Suppl. 2):N30-N36.
35. Cetani F., Pardi E., Ambrogini E., et al. Genetic analyses in familial isolated hyperparathyroidism: implication for clinical assessment and surgical management. Clin Endocrinol (Oxf) 2006, 64:146-152.
36. Kennett S., Pollick H. Jaw lesions in familial hyperparathyroidism. Oral Surg Oral Med Oral Pathol 1971, 31:502-510.
37. Jackson C.E., Norum R.A., Boyd S.B., et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 1990, 108:1006-1012. discussion 12-13.
38. Cavaco B.M., Barros L., Pannett A.A., et al. The hyperparathyroidism-jaw tumour syndrome in a Portuguese kindred. QJM 2001, 94:213-222.
39. Howell V.M., Haven C.J., Kahnoski K., et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 2003, 40:657-663.
40. Shattuck T.M., Valimaki S., Obara T., et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 2003, 349:1722-1729.
41. Cetani F., Pardi E., Borsari S., et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab 2004, 89:5583-5591.
42. Simonds W.F., Robbins C.M., Agarwal S.K., Hendy G.N., Carpten J.D., Marx S.J. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab 2004, 89:96-102.
43. Warner J., Epstein M., Sweet A., et al. Genetic testing in familial isolated hyperparathyroidism: unexpected results and their implications. J Med Genet 2004, 41:155-160.
44. Villablanca A., Calender A., Forsberg L., et al. Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 2004, 41:e32.
45. Bradley K.J., Cavaco B.M., Bowl M.R., et al. Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf) 2006, 64:299-306.
46. Bradley K.J., Cavaco B.M., Bowl M.R., Harding B., Young A., Thakker R.V. Utilisation of a cryptic non-canonical donor splice site of the gene encoding parafibromin is associated with familial isolated primary hyperparathyroidism. J Med Genet 2005, 42:e51.
47. Guarnieri V., Scillitani A., Muscarella L.A., et al. Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: implications for cancer surveillance. J Clin Endocrinol Metab 2006, 91:2827-2832.
48. Kelly T.G., Shattuck T.M., Reyes-Mugica M., et al. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J Bone Miner Res 2006, 21:1666-1671.
49. Cetani F., Ambrogini E., Viacava P., et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?. Eur J Endocrinol 2007, 156:547-554.
50. Hewitt K.M., Sharma P.K., Samowitz W., Hobbs M. Aberrant methylation of the HRPT2 gene in parathyroid carcinoma. Ann Otol Rhinol Laryngol 2007, 116:928-933.
51. Krebs L.J., Shattuck T.M., Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 2005, 90:5015-5017.
52. Rozenblatt-Rosen O., Hughes C.M., Nannepaga S.J., et al. The parafibromin tumor suppressor protein is part of a human PAF1 complex. Mol Cell Biol 2005, 25:612-620.
53. Yart A., Gstaiger M., Wirbelauer C., et al. The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 2005, 25:5052-5060.
54. Hahn M.A., Marsh D.J. Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene 2005, 24:6241-6248.
55. Lin L., Czapiga M., Nini L., Zhang J.H., Simonds W.F. Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Mol Cancer Res 2007, 5:183-193.
56. Bradley K.J., Bowl M.R., Williams S.E., et al. Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 2007, 26:1213-1221.
57. Hahn M.A., Marsh D.J. Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett 2007, 581:5070-5074.
58. Woodard G.E., Lin L., Zhang J.H., Agarwal S.K., Marx S.J., Simonds W.F. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 2005, 24:1272-1276.
59. Zhang C., Kong D., Tan M.H., et al. Parafibromin inhibits cancer cell growth and causes G1 phase arrest. Biochem Biophys Res Commun 2006, 350:17-24.
60. Iwata T., Mizusawa N., Taketani Y., Itakura M., Yoshimoto K. Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen. Oncogene 2007, 26:6176-6183.
61. Mosimann C., Hausmann G., Basler K. Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 2006, 125:327-341.
62. Brown J.J., Mohamed H., Williams-Smith L., Osborne R., Coker J., Yee B. Primary hyperparathyroidism secondary to simultaneous bilateral parathyroid carcinoma. Ear Nose Throat J 2002, 81:395-398. pp. 400-401.
63. Flye M.W., Brennan M.F. Surgical resection of metastatic parathyroid carcinoma. Ann Surg 1981, 193:425-435.
64. van Heerden J.A., Weiland L.H., ReMine W.H., Walls J.T., Purnell D.C. Cancer of the parathyroid glands. Arch Surg 1979, 114:475-480.
65. Bondeson L., Sandelin K., Grimelius L. Histopathological variables and DNA cytometry in parathyroid carcinoma. Am J Surg Pathol 1993, 17:820-829.
66. DeLellis R.A. Parathyroid carcinoma: an overview. Adv Anat Pathol 2005, 12:53-61.
67. Shane E. Clinical review 122: parathyroid carcinoma. J Clin Endocrinol Metab 2001, 86:485-493.
68. Fujimoto Y., Obara T. How to recognize and treat parathyroid carcinoma. Surg Clin N Am 1987, 67:343-357.
69. Holmes E.C., Morton D.L., Ketcham A.S. Parathyroid carcinoma: a collective review. Ann Surg 1969, 169:631-640.
70. Rubin M.R., Silverberg S.J., D'Amour P., et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem 2007, 53:1470-1476.
71. Rubin M.R., Bilezikian J.P., Birken S., Silverberg S.J. Human chorionic gonadotropin measurements in parathyroid carcinoma. Eur J Endocrinol 2008, 159:469-474.
72. Wilkins B.J., Lewis J.S. Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. Head Neck Pathol 2009, 3:140-149.
73. Levin K.E., Galante M., Clark O.H. Parathyroid carcinoma versus parathyroid adenoma in patients with profound hypercalcemia. Surgery 1987, 101:649-660.
74. Rubello D., Casara D., Dwamena B.A., Shapiro B. Parathyroid carcinoma. A concise review. Minerva Endocrinol 2001, 26:59-64.
75. Thompson S.D., Prichard A.J. The management of parathyroid carcinoma. Curr Opin Otolaryngol Head Neck Surg 2004, 12:93-97.
76. Spinelli C., Bonadio A.G., Berti P., Materazzi G., Miccoli P. Cutaneous spreading of parathyroid carcinoma after fine needle aspiration cytology. J Endocrinol Invest 2000, 23:255-257.
77. Smith J.F., Coombs R.R. Histological diagnosis of carcinoma of the parathyroid gland. J Clin Pathol 1984, 37:1370-1378.
78. Schantz A., Castleman B. Parathyroid carcinoma. A study of 70 cases. Cancer 1973, 31:600-605.
79. McKeown P.P., McGarity W.C., Sewell C.W. Carcinoma of the parathyroid gland: is it overdiagnosed? A report of three cases. Am J Surg 1984, 147:292-298.
80. Snover D.C., Foucar K. Mitotic activity in benign parathyroid disease. Am J Clin Pathol 1981, 75:345-347.
81. Grimelius L., Johansson H. Pathology of parathyroid tumors. Semin Surg Oncol 1997, 13:142-154.
82. Juhlin C., Akerstrom G., Klareskog L., et al. Monoclonal antiparathyroid antibodies revealing defect expression of a calcium receptor mechanism in hyperparathyroidism. World J Surg 1988, 12:552-558.
83. Busaidy N.L., Jimenez C., Habra M.A., et al. Parathyroid carcinoma: a 22-year experience. Head Neck 2004, 26:716-726.
84. Clayman G.L., Gonzalez H.E., El-Naggar A., Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation and interdisciplinary management. Cancer 2004, 100:900-905.
85. Kameyama K., Takami H., Umemura S., et al. PCNA and Ki-67 as prognostic markers in human parathyroid carcinomas. Ann Surg Oncol 2000, 7:301-304.
86. Rubin M.R., Silverberg S.J. Editorial: HRPT2 in parathyroid cancer: a piece of the puzzle. J Clin Endocrinol Metab 2005, 90:5505-5507.
87. Lloyd R.V., Erickson L.A., Jin L., et al. p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999, 154:313-323.
88. Bergero N., De Pompa R., Sacerdote C., et al. Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Hum Pathol 2005, 36:908-914.
89. Fernandez-Ranvier G.G., Khanafshar E., Tacha D., et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 2009, 115:334-344.
90. Kettle A.G., O'Doherty M.J. Parathyroid imaging: how good is it and how should it be done?. Semin Nucl Med 2006, 36:206-211.
91. Kebebew E., Arici C., Duh Q.Y., Clark O.H. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 2001, 136:878-885.
92. Castellani M., Reschini E., Longari V., et al. Role of Tc-99m sestamibi scintigraphy in the diagnosis and surgical decision-making process in primary hyperparathyroid disease. Clin Nucl Med 2001, 26:139-144.
93. James C., Starks M., MacGillivray D.C., White J. The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism. Surg Oncol Clin N Am 1999, 8:145-169.
94. Fraker D.L. Update on the management of parathyroid tumors. Curr Opin Oncol 2000, 12:41-48.
95. Stark D.D., Gooding G.A., Moss A.A., Clark O.H., Ovenfors C.O. Parathyroid imaging: comparison of high-resolution CT and high-resolution sonography. AJR Am J Roentgenol 1983, 141:633-638.
96. Weber A.L., Randolph G., Aksoy F.G. The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. Radiol Clin N Am 2000, 38:1105-1129.
97. Kemps B., van Ufford H.Q., Creyghton W., et al. Brown tumors simulating metastases on FDG PET in a patient with parathyroid carcinoma. Eur J Nucl Med Mol Imag 2008, 35:850.
98. Buck A.K., Nekolla S., Ziegler S., et al. SPECT/CT. J Nucl Med 2008, 49:1305-1319.
99. Kebebew E., Clark O.H. Parathyroid adenoma, hyperplasia, and carcinoma: localization, technical details of primary neck exploration, and treatment of hypercalcemic crisis. Surg Oncol Clin N Am 1998, 7:721-748.
100. Kebebew E. Parathyroid carcinoma. Curr Treat Options Oncol 2001, 2:347-354.
101. Shortell C.K., Andrus C.H., Phillips C.E., Schwartz S.I. Carcinoma of the parathyroid gland: a 30-year experience. Surgery 1991, 110:704-708.
102. Hoelting T., Weber T., Werner J., Herfarth C. Surgical treatment of parathyroid carcinoma. Oncol Rep 2001, 8:931-934.
103. Fujimoto Y., Obara T., Ito Y., Kodama T., Nobori M., Ebihara S. Localization and surgical resection of metastatic parathyroid carcinoma. World J Surg 1986, 10:539-547.
104. Iacobone M., Lumachi F., Favia G. Up-to-date on parathyroid carcinoma: analysis of an experience of 19 cases. J Surg Oncol 2004, 88:223-228.
105. Obara T., Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg 1991, 15:738-744.
106. McCance D.R., Kenny B.D., Sloan J.M., Russell C.F., Hadden D.R. Parathyroid carcinoma: a review. J R Soc Med 1987, 80:505-509.
107. Mezhir J.J., Melis M., Headley R.C., Pai R.K., Posner M.C., Kaplan E.L. Successful palliation of hypercalcemia secondary to metastatic parathyroid cancer: an unusual indication for hepatic resection. J Hepatobiliary Pancreat Surg 2007, 14:410-413.
108. Chow E., Tsang R.W., Brierley J.D., Filice S. Parathyroid carcinoma - the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1998, 41:569-572.
109. Munson N.D., Foote R.L., Northcutt R.C., et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy?. Cancer 2003, 98:2378-2384.
110. Calandra D.B., Chejfec G., Foy B.K., Lawrence A.M., Paloyan E. Parathyroid carcinoma: biochemical and pathologic response to DTIC. Surgery 1984, 96:1132-1137.
111. Bukowski R.M., Sheeler L., Cunningham J., Esselstyn C. Successful combination chemotherapy for metastatic parathyroid carcinoma. Arch Intern Med 1984, 144:399-400.
112. Eurelings M., Frijns C.J., Jeurissen F.J. Painful ophthalmoplegia from metastatic nonproducing parathyroid carcinoma: case study and review of the literature. Neuro Oncol 2002, 4:44-48.
113. Mulder J.E.B.J. Acute management of hypercalcemia. The parathyroids: basic and clinical concepts 2001, 729-741. Academic Press, San Diego. 2nd ed. J.P. Bilezikian, M.A. Levine (Eds.).
114. Warrell R.P., Issacs M., Alcock N.W., Bockman R.S. Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma. Ann Intern Med 1987, 107:683-686.
115. Koyano H., Shishiba Y., Shimizu T., et al. Successful treatment by surgical removal of bone metastasis producing PTH: new approach to the management of metastatic parathyroid carcinoma. Intern Med 1994, 33:697-702.
116. Denney A.M., Watts N.B. The effect of octreotide on parathyroid carcinoma. J Clin Endocrinol Metab 2004, 89:1016.
117. Bradwell A.R., Harvey T.C. Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 1999, 353:370-373.
118. Betea D., Bradwell A.R., Harvey T.C., et al. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. J Clin Endocrinol Metab 2004, 89:3413-3420.
119. Schott M., Feldkamp J., Schattenberg D., et al. Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 2000, 142:300-306.
120. Nemeth E.F., Steffey M.E., Hammerland L.G., et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 1998, 95:4040-4045.
121. Silverberg S.J., Rubin M.R., Faiman C., et al. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab 2007, 92:3803-3808.
122. Kleinpeter K.P., Lovato J.F., Clark P.B., et al. Is parathyroid carcinoma indeed a lethal disease?. Ann Surg Oncol 2005, 12:260-266.
123. Sandelin K., Tullgren O., Farnebo L.O. Clinical course of metastatic parathyroid cancer. World J Surg 1994, 18:594-598. discussion 9.